PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma (Q33690142)

24450858

28 July 2017

title

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma (English)

1 reference

28 July 2017

1 reference

ChEBI release 2020-05-28

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Wojciech Jurczak

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ian W. Flinn

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Andrew Davies

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Pier Luigi Zinzani

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Gilles Salles

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

11

Kristie A Blum

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

2

Brad S Kahl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

12

Andre H Goy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Nina D Wagner-Johnston

4

object named as

Nina D Wagner-Johnston

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

3

Sven de Vos

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

5

Stephen J Schuster

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Christopher R Flowers

8

object named as

Christopher R Flowers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

10

Andreas Viardot

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

17

Langdon L Miller

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

15

Martin Dreyling

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Peter Martin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Dave Johnson

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Leanne Holes

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Daniel Li

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Roger D Dansey

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Wayne R Godfrey

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

22 January 2014

1 reference

24450858

The New England Journal of Medicine

28 July 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

370

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1008-1018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

1 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Management of indolent lymphoma: where are we now and where are we going

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Radioimmunotherapy for B-cell non-hodgkin lymphomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

21 June 2018

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

The emerging mechanisms of isoform-specific PI3K signalling

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Bendamustine: rebirth of an old drug

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Ibritumomab tiuxetan for non-Hodgkin's lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Natural history of and therapy for the indolent non-Hodgkin's lymphomas.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Optimal two-stage designs for phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

PI3K signalling: the path to discovery and understanding.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Revised response criteria for malignant lymphoma

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4039496

Karnofsky performance status revisited: reliability, validity, and guidelines

30 October 2018

1 reference

PubMed

12 December 2020

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab

1 reference

PubMed

12 December 2020

How I treat indolent lymphoma

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1314583

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24450858%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

24450858

1 reference